Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 Next >
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q4 2024 Aide-mémoire
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi in discussions to sell a controlling stake in Opella
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q3 2024 Aide mémoire
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Online availability of Sanofi’s half-year financial report for 2024
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.